Learning to Think at Lightspeed

mylisa - Stock.adobe.com

World leaders have set ambitious goals to respond more swiftly to the next pandemic, including the United States’ goal to design, test, and review a new vaccine just 100 days after a pandemic declaration and to produce enough vaccines for the US and the world in 130 and 200 days. Past preparedness efforts have focused on innovation and reliability—culminating in the novel mRNA vaccines. Today, it’s important to consider diverse responses—and how the industry can make investments sustainable and “ready” for when an emergency happens.

Read this article in Pharmaceutical Technology’s The Real Message Behind Commercial mRNA Products eBook

About the author

Chris Spivey is editorial director of Pharmaceutical Technology.

Article details

Pharmaceutical Technology
eBook: The Real Message Behind Commercial mRNA Products
April 2023
Pages: 6–11

Citation

When referring to this article, please cite it as Spivey, C. Learning to Think at Lightspeed. Pharmaceutical Technology's The Real Message Behind Commercial mRNA Products eBook (April 2023).